Acurx Pharmaceuticals (ACXP) Institutional Ownership $4.72 +0.17 (+3.74%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.64 -0.08 (-1.69%) As of 08/22/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Acurx Pharmaceuticals (NASDAQ:ACXP)CurrentInstitutional OwnershipPercentage11.53%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$14.28MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$969.32K Get ACXP Insider Trade Alerts Want to know when executives and insiders are buying or selling Acurx Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ACXP Institutional Buying and Selling by Quarter Acurx Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Armistice Capital LLC1,078,540$551K0.0%N/A70.126% 8/8/2025 Prospect Financial Services LLC296,776$152K0.1%-19.0%19.296% 8/8/2025 Geode Capital Management LLC146,404$75K0.0%-14.6%9.519% 8/6/2025 O Brien Greene & Co. Inc60,000$31K0.0%N/A0.195% 4/11/2025 Vanguard Capital Wealth Advisors67,500$26K0.0%N/A0.301% 4/11/2025 Prospect Financial Services LLC366,576$143K0.1%+11.4%1.637% 1/22/2025 Prospect Financial Services LLC329,076$268K0.1%+11.5%1.932% 11/16/2024 Geode Capital Management LLC146,500$278K0.0%+12.7%0.902% 10/15/2024 Prospect Financial Services LLC295,075$561K0.3%+6.1%1.862% 7/15/2024 Prospect Financial Services LLC278,100$626K0.5%+1.9%1.756% 4/23/2024 Prospect Financial Services LLC272,850$668K0.6%+6.9%1.732% 4/5/2024 NBC Securities Inc.14,000$34K0.0%N/A0.089% 2/20/2024 Prospect Financial Services LLC255,150$977K1.0%N/A1.853% 2/1/2024 Sigma Planning Corp10,000$38K0.0%N/A0.073% 11/15/2023 Armistice Capital LLC500,000$750K0.0%-57.7%3.843% 8/14/2023 One68 Global Capital LLC13,044$35K0.2%N/A0.101% 11/14/2022 Armistice Capital LLC1,066,000$3.20M0.1%N/A9.224% 8/12/2022 Semmax Financial Advisors Inc.5,879$28K0.0%+365.5%0.057% 8/1/2022 Castle Wealth Management LLC13,000$49K0.0%N/A0.127% 1/10/2022 Patriot Financial Group Insurance Agency LLC7,000$30K0.0%+75.0%0.069% 11/15/2021 Tocqueville Asset Management L.P.19,100$98K0.0%+91.0%0.189% 11/9/2021BlackRock Inc.6,515$33K0.0%N/A0.064% 8/16/2021 Tocqueville Asset Management L.P.10,000$64K0.0%N/A0.105% (Data available from 1/1/2016 forward) ACXP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ACXP shares? During the previous two years, the following institutional investors and hedge funds held shares of Acurx Pharmaceuticals shares: Armistice Capital LLC ($551K), Prospect Financial Services LLC ($152K), Geode Capital Management LLC ($75K), Sigma Planning Corp ($38K), NBC Securities Inc. ($34K), and O Brien Greene & Co. Inc ($31K), and Vanguard Capital Wealth Advisors ($26K).Learn more on Acurx Pharmaceuticals' institutional investors. What percentage of Acurx Pharmaceuticals' stock is owned by institutional investors? 11.53% of Acurx Pharmaceuticals' stock is owned by institutional investors. Learn more on ACXP's institutional investor holdings. Which institutional investors have been buying Acurx Pharmaceuticals' stock? The following institutional investors have purchased Acurx Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($1.08M), Prospect Financial Services LLC ($366.58K), Vanguard Capital Wealth Advisors ($67.50K), O Brien Greene & Co. Inc ($60K), Geode Capital Management LLC ($16.49K), NBC Securities Inc. ($14K), and Sigma Planning Corp ($10K). How much institutional buying is happening at Acurx Pharmaceuticals? Institutional investors have bought a total of 1,311,001 shares in the last 24 months. This purchase volume represents approximately $14.28M in transactions. Which of Acurx Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Acurx Pharmaceuticals stock in the last 24 months: Prospect Financial Services LLC ($69.80K), and Geode Capital Management LLC ($25.08K). How much institutional selling is happening at Acurx Pharmaceuticals? Institutional investors have sold a total of 94,883 shares in the last 24 months. This volume of shares sold represents approximately $969.32K in transactions. Related Companies Synergy CHC Major Shareholders Mural Oncology Major Shareholders CASI Pharmaceuticals Major Shareholders Trinity Biotech Major Shareholders Kezar Life Sciences Major Shareholders MIRA Pharmaceuticals Major Shareholders Rein Therapeutics Major Shareholders Tenax Therapeutics Major Shareholders Dyadic International Major Shareholders Medicus Pharma Major Shareholders This page (NASDAQ:ACXP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access